Eliem Therapeutics, Inc. (ELYM) Misses Q2 EPS by 181c
Tweet
Share
E-mailGet Alerts ELYM Hot Sheet
Join SI Premium – FREE
Eliem Therapeutics, Inc. (NASDAQ: ELYM) reported Q2 EPS of ($1.81), $1.81 worse than the analyst estimate of $0.00.
For earnings history and earnings-related data on Eliem Therapeutics, Inc. (ELYM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ackman adds Netflix, Visa and Mastercard in portfolio revamp
- Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
- Euroseas Ltd. (ESEA) Tops Q2 EPS by 61c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
